New Delhi: Dr Anthony Fauci, a top infectious disease official of the United States, on Wednesday said that drug makers will likely have produced a billion doses of COVID-19 vaccine by the end of 2021.
In an interview with a leading daily, Fauci said that as we get into 2021, manufacturers will have hundreds of millions and most likely billion doses by the end of 2021. Although, that also will depend on the effective vaccine actually being developed and approved. He added that even though one can never guarantee things with vaccine he is “cautiously optimistic.”
Fauci also warned of another cycle of infection. In the interview he added that he hopes that by the time we all get to 2021 and go around for another cycle of COVID-19 viral outbreak, things will be under control. He is optimistic that we would have a much better control after one full year from this winter.
According to the top health expert, they have a pretty comprehensive portfolio which is subsequently going into clinical trials. Out of the many he is optimistic that at least one vaccine will work and is safe by year end. The US is even spending billions of dollars on vaccines which are being produced by various companies. These include Moderna Inc, Novavax Inc, Johnson & Johnson, Pfizer Inc and Sanofi SA.
Additionally, on Wednesday Fauci during a livestreamed talk said that he had to hire security to protect himself and his family. This was after he and his family received death threats from people who object to his work on the COVID-19 pandemic and the science behind regulations.
On the line of vaccines against the COVID-19 Russia may become the world’s first country to approve coronavirus vaccine for public use. The coronavirus vaccine developed by Russian military and government researchers is currently undergoing phase 2 human trials. According to media reports, Russian government officials may get the COVID-19 vaccine approved for public use by August 10. The vaccine developed by Moscow’s Gamaleya Institute will be approved for public use with frontline workers getting first dosage of the vaccine.
On the other hand the Serum Institute of India (SII) has now asked for permission from the Drugs Controller General of India (DCGI) to conduct phase 2/3 human clinical trials for a potential vaccine ‘Covishield.’ The domestic pharma company has already partnered with AstraZeneca for the manufacture of the Oxford vaccine candidate.